ANIXNasdaq

Anixa Biosciences Inc

Healthcare·Oncology·Phase 1·San Jose, CA, United States
OncologyGene TherapyInfectious Disease

Anixa Biosciences Inc (ANIX): 10 pipeline candidates · ~23 mo cash runway. Updated within the last hour.

7.3/10

BioSniper Score

5-factor signal · derived from public data

Cash Runway6.4

23.1 months

Financial Health9.8

D/E 0.11 · 0% dilution

Pipeline Maturity4.0

Lead: Phase 1

Pipeline Breadth10.0

10 candidates

Catalyst MomentumN/A

N/A

Insider Signal6.5

1 buy · 0 sells (180d)

A transparent, data-derived signal for Anixa Biosciences Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

$88.5M

Cash

$1.5M

Quarterly Burn

$1.7M

Runway

23.1 mo

Revenue

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~May 2028
Today~25 mo out
Catalyst within runway

Pipeline (10 candidates)

Institutional Holdings

Source: SEC Form 13F · as of Mar 2026

Institutional holders

61

Total value held

$13.6M

HolderSharesValue
vanguard capital management llc2,629,964$6.8M
d.a. davidson & co.539,272$1.4M
geode capital management, llc364,731$941K
vanguard fiduciary trust co191,074$493K
marshall wace, llp173,179$447K
blackrock, inc.170,103$439K
state street corp159,040$410K
susquehanna international group, llp133,668$345K
lpl financial llc80,976$209K
northern trust corp66,825$172K

Showing top 10 of 61 institutional holders of Anixa Biosciences Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.

·1 FDA decision·CEO: Dr. Amit Kumar Ph.D.

Frequently asked questions

How many drug candidates are in Anixa Biosciences Inc's pipeline?

Anixa Biosciences Inc (ANIX) has 10 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is Anixa Biosciences Inc's lead drug candidate?

Anixa Biosciences Inc's most advanced tracked candidate is alpha-lactalbumin breast cancer vaccine (Phase 1) for Preventative vaccine against triple negative breast cancer (TNBC) and other breast cancers that express alpha-lactalbumin.

What is Anixa Biosciences Inc's cash runway?

Based on its most recent reported cash balance and quarterly burn rate, Anixa Biosciences Inc has approximately 23.1 months of cash runway.

What is Anixa Biosciences Inc's market capitalization?

Anixa Biosciences Inc's market capitalization is approximately $88.5M.

Who is the CEO of Anixa Biosciences Inc?

Dr. Amit Kumar Ph.D. is the chief executive officer of Anixa Biosciences Inc (ANIX).

Get the full picture on Anixa Biosciences Inc

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.